You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 4,160,025


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,160,025
Title: Method of producing a blood-coagulation-promoting preparation from human blood plasma
Abstract:In a method of producing a blood-coagulation-promoting preparation from human blood plasma, which preparation contains a new blood-coagulating substance called \"FEIBA\", human plasma with citrate ions is treated with water-insoluble inorganic coagulation-physiologically-surface-active substances in the absence of free calcium ions, thus generating \"FEIBA\", the water-insoluble substances are separated, the supernatant is treated with basic ion exchangers, wherein \"FEIBA\" and the coagulation factors II-VII-IX-X adhere to the ion exchangers, and \"FEIBA\" and the factors II-VII-IX-X are eluted and concentrated.
Inventor(s): Eibl; Johann (Vienna, AT), Schwarz; Otto (Vienna, AT), Elsinger; Fritz (Vienna, AT)
Assignee: Immuno Aktiengesellschaft fur chemisch-medizinische Produkte (Vienna, AT)
Application Number:05/822,679
Patent Claims:1. A method of producing a blood-coagulation promoting preparation having Factor VIII inhibitor bypassing activity comprising treating plasma containing coagulation Factors II, VII, IX and X in in the absence of free calcium ions with a water-insoluble inorganic coagulation-physiologically-surface-active substance selected from the group consisting of diatomaceous earths and substances composed of silicon dioxide and aluminum oxide to generate the Factor VIII inhibitor bypassing active (FEIBA) substance, said plasma being non-coagulating when treated with said surface-active substance; separating the water-insoluble substances; treating the supernatant with a basic ion exchanger to adsorb the FEIBA substance and said coagulation Factors II, VII, IX and X; eluting the FEIBA substance and the coagulation factors II, VII, IX and X from the basic ion exchanger; and concentrating the FEIBA substance and coagulation Factors II, VII, IX and X.

2. A method as set forth in claim 1, wherein said new substance FEIBA is generated while maintaining a pH-value of from 5.5 to 8.5, and a temperature of from 0.degree. to 30.degree. C.

3. A method as set forth in claim 1, wherein said water-insoluble, inorganic coagulation-physiologically-surface-active substances are used in an amount of from 0.05 to 5%, based on the amount of plasma used.

4. A method as set forth in claim 1, wherein said water-insoluble, inorganic coagulation-physiologically-surface-active substances are used in an amount of from 0.1 to 1%, based on the amount of plasma used.

5. The method according to claim 1, wherein the plasma is selected from the group consisting of citrated plasma, cryosupernatant of frozen plasma, and plasma supernatant of Cohn's precipitate I.

6. A method according to claim 1, in which the basic ion exchanger is a high molecular weight substance containing diethylaminoethyl groups.

7. A method as set forth in claim 1, wherein said water-insoluble inorganic coagulation-physiologically-surface-active substance is celite.

8. A method as set forth in claim 1, wherein said water-insoluble inorganic coagulation-physiologically-surface-active substance is kaolin.

9. A preparation having Factor VIII inhibitor bypassing activity containing as an active ingredient in an amount effective to provide said Factor VIII inhibitor bypassing activity, a Factor VIII inhibitor bypassing active (FEIBA) substance which is produced by treating plasma containing coagulation Factors II, VII, IX and X in the absence of free calcium ions with a water-insoluble inorganic-coagulation-physiologically-surface-active substance selected from the group consisting of diatomaceous earths and substances composed of silicon dioxide and aluminum oxide to generate the FEIBA substance, said plasma being non-coagulating when treated with said surface-active substance; separating the water-insoluble substances; treating the supernatant with a basic ion exchanger to adsorb the FEIBA substance and said coagulation Factors II, VII, IX and X; eluting the FEIBA substance and the coagulation Factors II, VII, IX and X from the basic ion exchanger; and concentrating the FEIBA substance and coagulation Factors II, VII, IX and X.

10. A preparation according to claim 9 wherein there is a certain ratio between the activities of the coagulation factors II-VII-IX-X and the FEIB-activity, said ratio being expressed in units, one unit of the coagulation factors II-VII-IX-X corresponding to the activity of the coagulation factors II-VII-IX-X contained on an average in 1 ml of fresh human citrated plasma, and one FEIBA-unit corresponding to that FEIB-activity which reduces the activated partial thromboplastin time of a high-titer factor-VIII-inhibitor-plasma to half of the blank value, and wherein said ratio is between 0.1 and 10.

11. A preparation as set forth in claim 10, wherein said ratio is between 0.5 and 2.

12. A preparation according to claim 9 wherein the specific amidolytic activity as regards the substrates N-benzoyl-L-phenylalanyl-L-valyl-L-arginine-p-nitroanilide.HCl, N-benzoyl-L-isoleucyl-L-glutamyl-L-glycyl-L-arginyl-p-nitroanilide.HCl, D-valyl-L-leucyl-L-lysyl-p-nitroanilide.2HCl, i.e. .DELTA. OD.10.sup.3 /min-values per 1 FEIBA-unit do not exceed 4, and .DELTA.OD.10.sup.3 /min-values per 1 unit of coagulation factor II-VII-IX-X activity do not exceed 3, one unit of the coagulation factors II-VII-IX-X corresponding to the activity of the coagulation factors II-VII-IX-X contained on an average in 1 ml of fresh human citrated plasma, and one FEIBA-unit corresponding to that FEIB-activity which reduces the activated partial thromboplastin time of a high-titer factor-VIII-inhibitor-plasma to half of the blank value.

13. A preparation according to claim 9, wherein the specific amidolytic activity as regards the substrates N-benzoyl-L-phenylalanyl-L-valyl-L-arginine-p-nitroanilide.HCl, N-benzoyl-L-isoleucyl-L-glutamyl-L-glycyl-L-arginyl-p-nitroanilide.HCl, D-valyl-L-leucyl-L-lysyl-p-nitroanilide.2HCl, i.e. .DELTA. OD.10.sup.3 /min-values per 1 FEIBA-unit are less than 3, and .DELTA. OD.10.sup.3 /min-values per 1 unit of coagulation factor II-VII-IX-X activity are less than 2, one unit of the coagulation factors II-VII-IX-X corresponding to the activity of the coagulation fractors II-VII-IX-X contained on an average in 1 ml of fresh human citrated plasma, and one FEIBA-unit corresponding to that FEIB-activity which reduces the activated partial thromboplastin time of a high-titer factor-VIII-inhibitor-plasma to half of the blank value.

14. A preparation according to claim 9 wherein the ratio of thrombin activity to FEIB-activity does not exceed 0.02, the thrombin activity being expressed in NIH-units and the FEIB-activity being expressed in FEIBA-units, one FEIBA-unit corresponding to that FEIB-activity which reduces the activated partial thromboplastin time of a high-titer factor-VIII-inhibitor-plasma to half of the blank value.

15. A method for promoting the coagulation of blood containing an inhibitor to Factor VIII which comprises administering to a patient having blood containing an inhibitor to Factor VIII, an amount, effective to provide Factor VIII inhibitor by-passing activity, of a Factor VIII inhibitor by-passing active (FEIBA) preparation which is produced by treating plasma containing coagulation Factors II, VII, IX and X with a water-insoluble inorganic coagulation-physiologically-surface-active substance selected from the group consisting of diatomaceous earths and substances composed of silicon dioxide and aluminum oxide to generate the FEIBA substance, said plasma being non-coagulating when treated with said surface active substance; separating the water-insoluble substances; treating the supernatant with a basic ion exchanger to adsorb the FEIBA substance and the coagulation Factors II, VII, IX and X; eluting the FEIBA substance and said coagulation Factors II, VII, IX and X from the basic ion exchanger; and concentrating the FEIBA substance and said coagulation Factors II, VII, IX and X.

Details for Patent 4,160,025

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Baxalta Us Inc. AUTOPLEX, FEIBA NF, FEIBA VH anti-inhibitor coagulant complex For Injection 101447 12/21/1979 ⤷  Try a Trial 1996-08-30
Baxalta Us Inc. AUTOPLEX, FEIBA NF, FEIBA VH anti-inhibitor coagulant complex For Injection 101447 07/31/2000 ⤷  Try a Trial 1996-08-30
Baxalta Us Inc. AUTOPLEX, FEIBA NF, FEIBA VH anti-inhibitor coagulant complex For Injection 101447 08/11/2005 ⤷  Try a Trial 1996-08-30
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.